PROGRAM DESCRIPTION

According to the American Association of Clinical Endocrinologists (AACE), more than 60% of diabetes mellitus (DM) patients do not reach HbA1c target goals, despite overwhelming evidence that strict glucose management can reduce the development of chronic complications in these patients. Advances in the understanding of glucose homeostasis have helped identify new therapeutic targets, such as incretin hormones, which may address some of the unmet needs of conventional type 2 diabetes medications.

This program will explore the role of incretin hormones in the management of glucose homeostasis; identify the unique mechanisms of action and safety and tolerability profiles of incretin-based therapies; and discuss why, when, and how incretin-based therapies should be considered in the treatment of type 2 diabetes.

Faculty

	John (Jack) Leahy, MD—Chair (read bio) Chief, Division of Endocrinology, Diabetes and Metabolism Professor of Medicine University of Vermont College of Medicine Colchester, VT
	Harold E. Lebovitz, MD, FACE (read bio) Professor of Medicine State University of New York Health Science Center at Brooklyn Staten Island, NY
	Zachary T. Bloomgarden, MD (read bio) Clinical Professor, Department of Medicine Mount Sinai School of Medicine New York, NY

TARGET AUDIENCE

This program was developed for primary care clinicians and other medical professionals who treat patients with type 2 diabetes.

EDUCATIONAL OBJECTIVES

This program is designed to address the following IOM competencies: provide patient-centered care and employ evidence-based practice.

At the conclusion of this activity, participants should be able to demonstrate the ability to:

1. Explain and compare the safety, efficacy, and tolerability of glucose- lowering therapies available for the management of type 2 DM
2. Explain the mechanisms of action of incretin-based therapies and discuss their place in the treatment algorithm for type 2 DM management
3. Discuss cardiovascular outcomes in the tight glucose control trials and outline strategies to reduce the risk of hypoglycemia associated with current DM management

ACCREDITATION

The Potomac Center for Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

DESIGNATION STATEMENT

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.5 AMA PRA Category 1 credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

DISCLOSURE POLICY

Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

All persons in a position to control the content of a continuing medical education program sponsored by the Potomac Center for Medical Education are required to disclose any relevant financial relationships with any commercial interest to PCME, as well as to learners. All conflicts are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners. Disclosures will be made known to the participants prior to the activity.

The content of this activity was vetted by an external medical reviewer to assure objectivity and that the activity is free of commercial bias.

The faculty reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

John (Jack) Leahy, MD: Consultant: Bristol-Myers Squibb, Daiichi-Sankyo, Merck, Novo Nordisk, Sanofi Aventis; Speaker: Bristol-Myers Squibb, Merck

Harold E. Lebovitz, MD, FACE: Consultant: AstraZeneca, Enzymotec, Metacure, Novo Nordisk, Sanofi Aventis; Speaker: GlaxoSmithKline, Eli Lilly; Advisory Board: Amylin Corporation, Biocon Pharma, Metacure; Share Holder: Amylin Corporation, Merck

Zachary T. Bloomgarden, MD: Speakers Bureau: Merck, Novo Nordisk, Lilly, Amylin, Daiichi-Sankyo, GlaxoSmithKline; Advisory Panel: Medtronic, Takeda, Merck, AtheroGenics Inc., CV Therapeutics, Bristol-Myers Squibb, AstraZeneca; Stock/Shareholder: Novartis, Abbott, Bard, Medtronic, Millipore, Roche; Consultant: Novartis, Dainippon Sumitomo Pharma America, Forest Laboratories, Nastech, Daiichi-Sankyo

Non-faculty content contributors and/or reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:

Carole Drexel, PhD; Kathy Merlo; Bradley Pine; Jay Katz; Blair St. Amand; Dana Simpler, MD: Nothing to Disclose

FDA Disclosure

The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.

SYSTEM REQUIREMENTS

In order to view this presentation, your computer must have audio capabilities (working speakers or headphones) and must have an Adobe Flash Player. The Adobe Flash Player can be downloaded here.

 

Sponsored by:

This program is supported through an educational grant from Amylin Pharmaceuticals, Inc. and Lilly USA, LLC

By clicking this button you are agreeing that you have read and understood the CME Statements above.